F-tag 772 Explained: Pharmacy Procedures & Pharmacist Review Compliance for SNFs

What CMS Requires: §483.45(b)(1)–(3) and F-772

Under 42 CFR §483.45(b)(1)–(3), every skilled nursing facility must establish and maintain a pharmaceutical-services program that gives a licensed pharmacist a defined oversight role, runs an in-service program for the nursing staff, and operates inside a documented set of written procedures covering every drug that enters the building from the moment of acquisition to the moment of destruction or return. F-tag 772 is the program-level F-tag for that entire framework.

F-772 is the F-tag surveyors cite when none of the smaller findings make sense in isolation — when the labeled vial problem (F-761) keeps happening because the procedure that should prevent it isn't on paper, when the DRR findings (F-755) keep going unaddressed because the oversight chain back to the DON is broken, or when the facility has no documented bridging plan during a pharmacy transition. It wraps F-755 and F-761 in a single program-level system, and surveyors will reach for it whenever they find that the smaller F-tags are symptoms of a larger procedural gap.

F-772 covers three distinct regulatory requirements codified across §483.45(b)(1)–(3):

Surveyors don't separate these sections in practice. They pull the procedures binder, the consultant-pharmacist sign-in log, the DRR cadence, and the QAPI minutes, then walk backward to the resident. A missing version date on the written procedure will land under (b)(1); an unsigned consultant visit will land under (b)(2); a DRR finding the DON never saw will land under (b)(3). Each finding alone is enough for the F-772 citation; multiple findings push scope and severity upward, and often bring F-755 and F-761 citations along with them.

The Written Procedures Chain

The pharmaceutical-services program in a well-run SNF is six interlocking routines. They run on different cadences but they have to be consistent across the building — because surveyors will sample from each, and they will look for evidence that the documented procedure is what staff actually do.

1. Acquisition & Receipt Control

Every medication entering the building must arrive through a documented channel: a pharmacy delivery with a matching invoice, a unit-dose return reconciled against a prior MAR, a controlled-substance delivery logged on receipt. The procedure names how deliveries are received, who verifies the count and the lot, where deliveries are signed in, and how discrepancies are escalated before stock is admitted to the medication room. Surveyors will pull a sample of controlled-substance deliveries, follow the receipt chain to the perpetual inventory under F-761, and write an F-772 finding whenever the written procedure says one thing and the actual workflow does another.

2. Compounding & Dispensing

When the facility compounds or repackages medications — even something as routine as splitting unit-dose cards for a half-dose order — the written procedure must spell out who does it, under what conditions, and which USP chapter applies. USP <795> governs non-sterile compounding; USP <797> governs sterile compounding. Most SNFs outsource sterile compounding to the pharmacy, but the facility's procedure still needs to define the hand-off and the verification step for any product that arrives compounded, and it must address beyond-use dating for anything the facility handles in-house. A procedure that says "we don't compound" without addressing the receiving side is itself an F-772 gap.

3. Administration Chain

The administration chain is where F-755 findings connect back to F-772. The written procedure should define the order-to-administration path, the bar-code or manual check that confirms the right drug to the right resident, the documentation step on the MAR, the hand-off for PRN administrations, and the escalation path when a dose is held or refused. Surveyors will read the procedure and then watch nurses at the cart — the gap between the two is where F-755 and F-772 citations are born together.

4. Storage Chain

The storage chain under F-772 is the program-level answer to the storage requirements under F-761. The procedure should describe how the medication room is organized, how access keys are controlled, how ambient and refrigerated temperatures are monitored, how the controlled-substance compartment is secured, and how after-hours emergency medication access is handled. Surveyors will look for the procedure that addresses "what we do when we need a drug at 2 a.m. and the pharmacy isn't open" — if the written procedure doesn't describe the actual workflow, the citation is immediate.

5. Pharmacist Oversight & In-Service

The licensed pharmacist's oversight role is the bridge between F-772 and F-755. The procedure should name the consultant pharmacist, define the visit cadence, document the in-service topics and the attendance roster, describe how the DRR findings are communicated, and explain how the pharmacist participates in QAPI. Surveyors will pull the consultant agreement, the sign-in log, the in-service roster, and the QAPI minutes to verify that the documented oversight actually happens, and they will write F-772 when any link in the chain is missing or undocumented.

6. Destruction, Return & Recall Response

Discontinued, expired, contaminated, or recalled medications must leave active stock through a documented pathway: pharmacy return, on-site destruction, or recall response. The procedure should cover DEA Form-41 for controlled substances destroyed in-house, witness signatures, the recall response role (who receives the recall notice, who pulls affected stock, who notifies the DON), and the link to FDA MedWatch when an adverse drug event triggers a report. Surveyors will pull the destruction log, a recall-event entry, and any bridging plan that covers a vendor or coverage transition.

What Surveyors Audit for F-772

Surveyors run F-772 the same way they run DRR for F-755 — trace the program-level chain end-to-end, across departments and across months. They almost always start with the pharmacy contract and consultant agreement, then walk the procedures binder, the DRR cadence, the in-service roster, and the QAPI minutes. Here's what they're checking at each step:

• Pharmacy contract & consultant agreement — Current contract defines the consultant's role, visit cadence, DRR responsibility, in-service participation, after-hours availability, and what happens during a coverage gap. A bridge plan covering pharmacy transitions is documented in writing and on file.
• Written procedures binder (paper or PDF) — Every procedure carries a revision date and a version number; staff can name the current revision; procedures match what nurses do at the cart. Surveyors will spot-check the binder against the cart workflow and write the citation when the two diverge.
• Pharmacist oversight schedule — Sign-in log shows documented consultant visits at the cadence named by the facility; visits are tied to DRR production and in-service delivery; after-hours coverage is named and reachable.
• In-service attendance & competency verification — Every nurse who administers medications has a current in-service on drug-related topics, including high-risk medications, controlled-substance handling, and recall response. Attendance roster matches actual staff assignments; competency verification is documented, not assumed.
• DRR integration into care plan & QAPI — DRR findings reach the attending physician on a documented cadence; physician responses are captured; care plan updates trace back to DRR findings; QAPI minutes show the DRR review happening at the program level. The cross-link here is the bridge into F-755.
• Vendor / coverage bridging plan — When the pharmacy changes vendors, when the consultant is on leave, or when coverage is interrupted, a documented bridging plan keeps DRR, oversight, and emergency medication access running without a gap. Surveyors will ask for the most recent bridging event and the documentation that kept the program running through it.
• Recall response log — Every drug recall that touches the facility produces a documented response: who received the notice, when affected stock was pulled, who notified the DON and the attending physicians, and which residents received the recalled medication. The link to FDA MedWatch is documented for any adverse drug event that escalates beyond the recall pull.
• Destruction log & DEA-required documentation — On-site destruction of controlled substances includes DEA Form-41 and witness signatures; pharmacy-return receipts are retained and cross-referenced; the destruction log ties back to the perpetual inventory under F-761. Surveyors will pull a sample of recent destruction events and check the paperwork.
• Audit of F-755 & F-761 documentation chain — Because F-755 and F-761 are the operational F-tags that live inside F-772, surveyors will spot-check that the documentation chain from procedures to DRR to labeling and storage is consistent. A gap in any of the three pulls F-772 forward.

This is why a working F-772 Pharmacy Procedures checklist matters: it walks the same program-level path a surveyor will, so your pre-survey audit covers the same territory in the same order — and the F-772, F-755, and F-761 documentation systems stay in lockstep.

Most Common F-772 Deficiencies

Across hundreds of F-tag deficiency citations, the patterns under F-772 are remarkably consistent from year to year. Here are the ones that keep showing up.

1. Broken Pharmacist Coverage During a Pharmacy Transition

The facility switches pharmacy vendors, or the consultant is on extended leave. DRR continuity is promised in the transition memo, but the actual sign-in log shows a six-week gap. Surveyors cite (b)(2) for the missing oversight and (b)(3) for the DRR cadence that stalled during the gap. The fix is a written bridging plan on file before the transition — naming the covering consultant, the cadence they're committing to, and the date the regular consultant resumes.

2. Procedures Binder With Missing Revision Dates

The "current" procedures binder on the medication-room shelf is dated two facility directors ago. The administrator says "we have procedures," but every procedure in the binder is missing a revision date, a version number, or a staff acknowledgment. Surveyors cite (b)(1) on the spot — and they cite it with the F-755 or F-761 gap the outdated procedure should have caught, because the procedure that prevents the gap has been quietly retired.

3. In-Service Program With Attendance Gaps

The in-service schedule shows quarterly topics on high-risk medications, controlled-substance handling, and recall response. But the attendance roster is missing the night-shift nurses, the per-diem nurses, and the agency staff who picked up weekend shifts. Surveyors will pull the actual staff schedule against the roster and write (b)(2) for every nurse who administered medications without documented in-service attendance.

4. No Recall Response Documented

FDA issues a recall on a medication the facility stocks. The pharmacy forwards the notice, the DON says they handled it, but no one recorded the receipt of the notice, the stock-pull, the resident-level notification, or the physician communication. Surveyors cite (b)(1) for the missing recall response procedure and (b)(2) for the missing documentation that the procedure ran. The fix is mechanical: every recall event produces a single-page event record with the five fields above, signed off by the DON and the consultant pharmacist.

5. DRR Findings That Never Reach the DON QAPI Loop

The consultant pharmacist completes monthly DRRs, identifies clinically significant irregularities, communicates them to the attending physicians, and sends a report to the facility. The report goes to a file. The QAPI minutes never surface the DRR findings as a discussion item. Surveyors cite (b)(3) for the missing QAPI bridge — and they cite it with F-755 because the DRR chain technically ran but the program-level improvement loop never engaged.

6. After-Hours Emergency Medication Access Procedure That Doesn't Match Practice

The written procedure says the on-call consultant authorizes emergency access; it says the backup pharmacy delivers; it says the on-call administrator receives the call. The actual workflow, on a 2 a.m. weekend shift, is that the charge nurse calls the DON's cell, the DON approves without calling the consultant, and the backup pharmacy delivers two hours later. Every step in the actual workflow diverges from the written procedure — and surveyors will write (b)(1) for the divergence without further investigation.

Pharmacy Procedures Documentation Checklist

Use this monthly as part of your mock survey process — ideally before any consultant or surveyor walk-through, so you can flag and fix gaps while you still control the timing:

High-Risk Scenarios Surveyors Probe

Surveyors focus their F-772 review on the pharmacy contract and consultant agreement (verifying coverage, scope, and bridging plan), the written procedures binder (revision dates and version numbers, not content alone), the licensed-pharmacist oversight schedule (missing visits, missing sign-ins, missing DRR production), the in-service roster (night-shift, per-diem, and agency coverage), the DRR-to-QAPI bridge (whether findings actually surface in QAPI), the vendor transition bridging plan (whether a recent transition holds up to scrutiny), and the recall response log (whether a recent recall got a single-page event record). Make sure those areas have tight, current documentation before survey week.

Frequently Asked Questions

What is F-tag 772 in a nursing home survey?

F-tag 772 covers the facility-level requirement that a skilled nursing facility establish and maintain written pharmacy procedures governing every drug from acquisition through destruction, with a licensed pharmacist providing oversight and an in-service program for nursing staff. It is the program-level pharmaceutical-services F-tag, sitting under 42 CFR §483.45(b)(1)–(3). Surveyors cite F-772 when the facility has no written procedures binder, when the procedures don't match what staff actually do, when pharmacist oversight is missing or undocumented, when the in-service program has attendance gaps, when DRR findings never reach the DON QAPI loop, or when the facility has no recall response plan in place.

How does F-772 relate to F-755 and F-761?

F-772 is the program-level pharmaceutical-services F-tag. F-755 (Drug Regimen Review) and F-761 (Labeling & Storage of Drugs) are subordinate tags that fall under F-772's umbrella. The acquisition-through-destruction chain named in §483.45(b)(1) is what gives F-755 and F-761 their operational backbone: F-755 is the periodic DRR cadence that runs inside that program, and F-761 is the storage leg of that chain. Surveyors frequently cite F-772 alongside F-755 or F-761 when the program-level system — not just an individual finding — has broken down.

What written procedures does F-772 require?

§483.45(b)(1) requires written procedures covering, at minimum: acquisition and receipt control of medications and biologicals; compounding and dispensing (consistent with USP <795> and USP <797> when applicable); administration, including the order-to-administration chain; storage and security; pharmacist oversight and in-service programming; and destruction or return of discontinued, expired, or recalled drugs. Each procedure must be current (dated and versioned), accessible to staff in a binder or staff-facing system, and actually used by the team — surveyors cross-check the binder against what nurses do at the cart.

How often must the consultant pharmacist visit under F-772?

CMS does not prescribe a single visitation frequency in §483.45(b)(2), but the standard requires that a licensed pharmacist provide oversight on a routine, documented cadence that is sufficient to perform and document the drug regimen review at the cadence required by F-755 and to support the facility's pharmaceutical-services program. In practice, most SNFs schedule monthly consultant-pharmacist visits that produce the monthly DRR, with same-day or next-day access for urgent issues and a bridging plan that covers any gap during vendor or coverage transitions.

What documentation do surveyors audit for F-772 compliance?

Surveyors audit the pharmacy contract and consultant agreement, the dated and versioned written procedures binder (paper or PDF), the licensed pharmacist oversight schedule and sign-in logs, in-service program attendance rosters and competency verifications, evidence that DRR findings route to the DON and QAPI committee, the vendor or coverage bridging plan for pharmacy transitions, the destruction log (including DEA Form-41 where applicable) and the recall response log, and the chain of audits for F-755 and F-761 documentation. Findings in any single area tend to surface findings in the others, because the regulator's question is whether the program actually works. Pair the F-772 reading with the F-772 Pharmacy Procedures checklist and the Pharmacy Compliance Bundle to keep the program-level documentation in survey shape.